Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
Gespeichert in:
| Titel: | Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy |
|---|---|
| Autoren: | Lorin Begré, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Caroline Scholtès, Charles Béguelin, Jürgen K Rockstroh, Huldrych F Günthard, Alexandra Calmy, Matthias Cavassini, Hans H Hirsch, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Gilles Wandeler, Fabien Zoulim, Andri Rauch, I Abela, K Aebi-Popp, A Anagnostopoulos, M Battegay, E Bernasconi, D L Braun, H C Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer, C A Fux, H F Günthard, A Hachfeld, D Haerry, B Hasse, H H Hirsch, M Hoffmann, I Hösli, M Huber, D Jackson-Perry, C R Kahlert, O Keiser, T Klimkait, R D Kouyos, H Kovari, K Kusejko, N Labhardt, K Leuzinger, B Martinez de Tejada, C Marzolini, K J Metzner, N Müller, J Nemeth, D Nicca, J Notter, P Paioni, G Pantaleo, M Perreau, A Rauch, L Salazar-Vizcaya, P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, G Wandeler, M Weisser, S Yerly |
| Weitere Verfasser: | Swiss HIV Cohort Study, Abela, I., Aebi-Popp, K., Anagnostopoulos, A., Battegay, M., Bernasconi, E., Braun, D.L., Bucher, H.C., Calmy, A., Cavassini, M., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, C.A., Günthard, H.F., Hachfeld, A., Haerry, D., Hasse, B., Hirsch, H.H., Hoffmann, M., Hösli, I., Huber, M., Jackson-Perry, D., Kahlert, C.R., Keiser, O., Klimkait, T., Kouyos, R.D., Kovari, H., Kusejko, K., Labhardt, N., Leuzinger, K., Martinez de Tejada, B., Marzolini, C., Metzner, K.J., Müller, N., Nemeth, J., Nicca, D., Notter, J., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Salazar-Vizcaya, L., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Weisser, M., Yerly, S. |
| Quelle: | J Infect Dis The Journal of infectious diseases, vol. 230, no. 4, pp. e954-e963 |
| Verlagsinformationen: | Oxford University Press (OUP), 2024. |
| Publikationsjahr: | 2024 |
| Schlagwörter: | Male, Adult, 0301 basic medicine, Hepatitis B virus, Anti-HIV Agents, hepatitis B core-related antigen, HIV Infections, Cohort Studies, 03 medical and health sciences, Hepatitis B, Chronic, Major Article, Humans, Tenofovir, 0303 health sciences, Hepatitis B Surface Antigens, Tenofovir/therapeutic use, HIV Infections/drug therapy, HIV Infections/blood, HIV Infections/complications, HIV Infections/virology, Hepatitis B Surface Antigens/blood, Female, RNA, Viral/blood, Hepatitis B virus/genetics, Hepatitis B Core Antigens/blood, Coinfection/drug therapy, Coinfection/virology, Middle Aged, Hepatitis B/drug therapy, Hepatitis B/blood, Hepatitis B/virology, Anti-HIV Agents/therapeutic use, Switzerland/epidemiology, Viral Load, Hepatitis B, Chronic/drug therapy, Hepatitis B, Chronic/blood, Hepatitis B, Chronic/virology, Hepatitis B, Chronic/complications, DNA, Viral/blood, HBV RNA, HIV, hepatitis B core–related antigen, hepatitis B virus, kinetics, Coinfection, Hepatitis B, Hepatitis B Core Antigens, 3. Good health, DNA, Viral, RNA, Viral, Switzerland |
| Beschreibung: | BackgroundWe evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study.MethodsWe included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates.ResultsHBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity.ConclusionsHBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss. |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf |
| Sprache: | English |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiae189 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/38626170 https://serval.unil.ch/notice/serval:BIB_7C1C4A6067C9 https://serval.unil.ch/resource/serval:BIB_7C1C4A6067C9.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_7C1C4A6067C92 |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Dokumentencode: | edsair.doi.dedup.....6e5eafa0f283491cc504fe2fa111e346 |
| Datenbank: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | BackgroundWe evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study.MethodsWe included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates.ResultsHBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity.ConclusionsHBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss. |
|---|---|
| ISSN: | 15376613 00221899 |
| DOI: | 10.1093/infdis/jiae189 |